Cellect: Rises on deal to study its stem cell tech for COVID-19 patients

Quoin Pharmaceuticals

18/05/2020 14:17

** Shares of Israel-based stem cell therapy co  APOP.O  rise
7.40% $3.34 premarket
    ** Co signs development agreement with international
consortium to study if stem cells treated with its technology
platform ApoGraft is effective in reducing lung-related issues
caused by COVID-19  urn:newsml:reuters.com:*:nPn9w1KgGa
    ** ApoGraft's technology is shown to prevent graft versus
host disease (GvHD) - when transplanted cells attack cells of
the patient receiving the transplant - in clinical trial
settings
    ** GvHD effects similar to cytokine storm, an overreaction
of the body's immune system, seen in COVID-19 patients and co
says approached by consortium use clinical data and regulatory
approvals of ApoGraft to speed up development of a cytokine
storm therapy for COVID-19 patients 
    ** Agreement allows co to receive royalties once products
are commercialized - APOP
    ** Up to last close, APOP stock down 40% YTD
    
       
    

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))